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Autophagy is a tightly modulated lysosomal degradation pathway. Genetic disorders of 
autophagy during nervous system development may lead to developmental delay, 
neurodegeneration and other neurological signs in children. Here we aimed to summarize 
single gene disorders that perturb various steps of autophagy pathway and their roles in the 
causation of childhood neurological diseases. Numerous childhood-onset disorders are caused 
by mutations that impact the autophagy pathway. These can manifest with a range of features 
including ataxia, spastic paraplegia, and intellectual disability. Defective proteins causing such 
diseases can interfere with autophagy flux at different stages of the itinerary. Defective 
autophagy may be an important contributor to the pathological features of various childhood 
neurodegenerative disease and lead to the accumulation of aberrant protein and dysfunctional 
organelles. Insights into the relevant cell biological processes may help understand 







What this paper adds: 
 
Numerous childhood-onset disorders are caused by mutations that impact the autophagy 
pathway.  
Defective autophagy is a feature of some mutations that cause ataxia, spastic paraplegia, and 
intellectual disability. 
Defective autophagy may be an important contributor to the pathological features of various 





Macroautophagy, henceforth autophagy, is a catabolic process that mediates the bulk 
degradation of cytosolic constituents by delivering them to lysosomes. While the process was 
originally identified as a key mechanism for maintaining cellular homeostasis, recent studies 
have shown that autophagy plays important roles in the degradation of damaged organelles, 
macromolecules, aggregate-prone proteins, bacteria and long-lived proteins inside the cell. 
While autophagy was largely considered as a non-selective bulk degradation process, recent 
studies have identified certain forms of autophagy which are selective for certain substrates 
including damaged organelles like mitochondria – mitophagy, peroxisomes – pexophagy; 
aggregate-prone proteins – aggrephagy; and pathogens – xenophagy.1 
Autophagy involves the formation and maturation of a double-membraned autophagosome that 
engulfs the cargo to be degraded, which is then delivered to the lysosomes to form an 
‘autolysosome’ (Figure 1). Autophagy involves several steps: initiation, nucleation, elongation, 
closure and fusion. Each step is tightly regulated by one or many protein(s)/protein complexes 
resulting in a pathway that is highly dynamic and responsive to various stimuli.2  
The classic marker that differentiates autophagosomes from other vesicles is the presence of 
lipidated ATG8 (ATG =  Autophagy related) ubiquitin-like family proteins on both sides of the 
vesicle. The ATG8 ubiquitin-like family of proteins in mammals consists of six members that 




*601242) (* refers to OMIM number) and GABA-A receptor-associated protein (GABARAP 
*605125).2 A defining event in autophagy is the conjugation of ATG8s/LC3 to membranes that 
become autophagosomes. This involves two ubiquitin-like reactions. First, ATG12 (*609608) 
an ubiquitin-like molecule, is conjugated to ATG5 (*604261) with the help of the enzymes 
ATG7 (*608760) and ATG10 (*610800); the ATG5-12 complex then combines with 
ATG16L1 (*610767) to form an ATG5-ATG12-ATG16L1 complex. In order for ATG8s/LC3 
to be accessible for the second set of conjugation reactions, pro-LC3 is converted into LC3-I 
by the cysteine protease ATG4A (*300663) exposing a free C-terminal glycine which then gets 
activated by ATG7. Next, the activated LC3-I is conjugated to phosphatidylethanolamine (PE) 
on autophagosome precursor membranes resulting in the formation of LC3-II, with the help of 
ATG3 (*609606) and the E3-like ligase activity of ATG5-ATG12-ATG16L1. The most 
common way of assessing autophagy therefore involves measuring the levels of LC3-II and 
counting the number of LC3-II puncta (autophagosomes) in cells.3  
Complex signalling processes upstream of these conjugation system respond to various stimuli 
to modulate autophagy. One of the most upstream elements in the signalling is the ULK1/2 
complex, which comprises UNC51-like kinase 1 (ULK1 *603168), or its homologue UNC51-
like kinase 2 (ULK2 *608650) together with ATG13 (*615088), 200 KDa FAK Family Kinase-
Interacting Protein (FIP200 *606837) and ATG101 ( *615089). The ULK1-ATG13 interaction 
depends on the phosphorylation status of ATG13, which is regulated by kinases like 
mechanistic target of rapamycin (mTOR *601231) and AMP-activated protein kinase (AMPK 
*602740). The phosphorylation of ATG13 by mTOR under nutrient-rich conditions hinders 
the ULK1-ATG13 interaction, thereby inactivating the complex. However, during starvation, 
ATG13 is dephosphorylated and forms an active ULK1 complex. In addition, ULK1 activation 
and the ULK1-AMPK interaction also depend on mTOR-mediated ULK1 phosphorylation. 
The active ULK1 complex then phosphorylates FIP200, which, in turn, helps recruit the next 
complex in the cascade, the VPS34 complex, at the autophagosome formation site. The core of 
the VPS34 complex consists of phosphatidylinositol 3-kinase class 3 (VPS34 kinase *602609) 
Beclin 1 (BECN1 *604378) and phosphatidylinositol 3-kinase regulatory subunit 4 (VPS15 
*602610), which can then associate with ATG14 (*0613515), UV radiation resistance-
associated gene (UVRAG *602493), or run domain and cysteine rich domain-containing 
beclin1-interacting protein (Rubicon *613516), resulting in three distinct complexes. The 
VPS34 complex generates phosphatidylinositol 3-phosphate (PI3P) at the autophagosome 




interacting with phosphoinositides 1 (WIPI) family proteins.4 WIPI2 (*609225) then directs 
the localization of ATG5-ATG12-ATG16L1 complex, thereby dictating the site for LC3 
membrane cojugation.5 WIPI2 may also regulate the trafficking of the transmembrane mATG9 
(ATG9,* 612204). While the function of mATG9 remains elusive, it has been speculated to 
assist membrane trafficking and delivery to the growing autophagosomes.2, 4 
Autophagy is an important buffer against various late-onset neurodegenerative diseases, since 
it mediates the clearance of toxic, aggregate-prone proteins like huntingtin, tau and alpha-
synuclein. Indeed, selective neuronal knockouts of key autophagy genes in mice lead to early 
lethality associated with the accumulation of aggregated proteins.2 
This review focuses specifically on the role of autophagy in neurological diseases with early-
onset (<20 years), which typically manifest in childhood (Table 1). Most of these disorders 
associated with defective autophagy follow autosomal-recessive inheritance, except BPAN, 
which is X-linked dominant.6  
Hereditary childhood ataxias  
Inherited ataxias comprise a genotypically and phenotypically diverse group of disorders that 
typically present with movement, balance and speech disturbance as a result of cerebellar 
dysfunction, which can be accompanied by a wide range of other signs, such as developmental 
delay, seizures or ocular abnormalities.7  
Null mutations of sorting nexin 14 (SNX14 *616105) cause a form of autosomal recessive 
syndromic cerebellar atrophy. The distinct features of the affected patients include intellectual 
disability, dysmorphic facies, sensorineural hearing loss and hepatosplenomegaly, 
phenotypically resembling lysosomal storage diseases.7 SNX14 binds phosphatidylinositol 3,5-
bisphosphate (PtdIns(3,5)P2) and localizes to late endosomes/lysosomes containing 
PtdIns(3,5)P2. Patient-derived neural progenitor cells carrying SNX14 mutations showed 
normal autophagosome formation, but slower autophagic flux after treatment with a 
proteasome inhibitor and excessive accumulation of autophagosomes after starvation. Taken 
together, the findings suggests that loss of SNX14 may disrupt autophagosome clearance by 
impairing lysosome function.7   
A homozygous missense mutation (E122D) in ATG5 (*604261) gene was identified in two 
siblings presenting with childhood ataxia associated with hypoplasia of the cerebellar vermis.1, 




controls. More interestingly, the levels of ATG5-ATG12 conjugate were severely reduced, 
although the expression levels of ATG5WT and ATG5E122D were similar. These data suggest 
that the reduction of autophagic flux in these patients might be due to defective lipidation of 
ATG8 family proteins.1, 8 Recently, a polymorphism of ATG5 gene (rs6568431) correlated with 
lower ATG5 expression was associated with childhood cerebral palsy (CP).9 However, the 
detailed mechanism about how this polymorphism causes CP has not been reported. 
Neurodegeneration with brain iron accumulation (NBIA) 
Neurodegeneration with brain iron accumulation (NBIA) encompasses a clinically and 
genetically heterogeneous collection of diseases characterized by iron deposition in the basal 
ganglia.6 The manifestations of NBIA include progressive dystonia, Parkinsonism, optic 
atrophy and neuropsychiatric abnormalities, with preservation of cognitive function in most 
cases. Interestingly, while iron accumulation remains a hallmark of NBIA, only two of the 
twelve causative genes are known to be directly involved in iron metabolism, with others 
having effects on a wide range of other cellular processes, including lipid metabolism or 
lysosome function. 
Beta-propeller protein-associated neurodegeneration (BPAN) 
Beta-propeller protein-associated neurodegeneration (BPAN) is a rare subtype of NBIA caused 
by X-linked dominant mutations of in the WDR45 gene encoding WIPI4.  Most described cases 
are females, with similar phenotypes seen in both sexes due to germline and somatic 
mosaicism. The disease was previously known as SENDA (static encephalopathy of childhood 
with neurodegeneration in adulthood). Patients manifest delay of motor and cognitive functions 
during early childhood, followed by rapid onset of progressive dystonia, Parkinsonism and 
dementia during adolescence or adulthood. BPAN patients exhibit prominent iron 
accumulation. As some WDR45 mutation-carrying patients show neurodevelopmental 
abnormalities before iron accumulation is apparent by brain imaging, iron accumulation may 
be the consequence rather than the cause of neurodevelopmental abnormalities. WIPIs are a 
family of proteins that can bind to a variety of phosphoinositides with different affinities. In 
CNS-specific Wdr45 knockout mice, the lipidated LC3 levels were increased and the 
autophagy substrate p62 together with ubiquitin-positive protein aggregates accumulated in 
swollen axons. Cells from BPAN patients manifest abnormal accumulations of lipidated LC3, 
together with increased colocalisation of LC3 and mATG9, which is usually absent on mature 




autophagosome maturation, potentially by regulating mATG9 localisation. The underlying 
mechanism of WIPI4 in BPAN needs to be studied further.  
Mitochondrial-membrane Protein-Associated Neurodegeneration (MPAN) 
MPAN, also called Hereditary spastic paraplegia type 43 (SPG43), is the third most common 
disease belonging to NBIA disorders. MPAN patients often suffer from cognitive decline, in 
addition to dystonia, gait and speech disturbance, or Parkinsonism.10 The age-of-onset is highly 
variable, but most patients present in childhood to early adulthood with slow progression.10 
The only gene locus confirmed for MPAN to date is Chromosome 19 open reading frame 12 
(C19orf12 *614297), which encodes a mitochondrial membrane protein sharing structure 
similarity with N-terminal regulatory domain of the magnesium transporter MgtE. C19orf12 
localizes at ER–mitochondria contact sites, which may be important for autophagosome 
formation and is translocated to the cytosol upon oxidative stress induction. In addition,  
overexpression of wild-type C19orf12 increased lipidated LC3 and reduced the amount of the 
autophagy substrate p62. However, overexpression of mislocalized mutants failed to promote 
autophagy and levels of basal autophagy remained unchanged during exposure to oxidative 
stress in HeLa cells.10. 
Hereditary spastic paraplegia (HSP) 
Hereditary spastic paraplegias (HSP) include a diverse group of inherited neurological diseases 
characterized by retrograde neurodegeneration of the longest corticospinal motor neurons, 
manifesting as lower limb hypertonia and weakness, typically accompanied with decreased 
vibration sense.11 Some autosomal recessive subtypes can present with additional 
complications (“complex HSP”), including varying degrees of ataxia, dementia or amyotrophy. 
Over 70 genetic loci have been mapped for HSPs (SPG1-72).11 70% of complex HSPs are 
caused by clinically indistinguishable mutations in SPG11 (*610844) and SPG15(*270700), 
manifesting as progressive leg spasticity, amyotrophy, learning difficulties and characteristic 
pigmentary retinopathy.11 The SPG11 and SPG15 protein products, spatacsin and spastizin, are 
required for lysosome reformation and interact with the AP5 complex to regulate late endosome 
membrane sorting.12 Spastizin also regulates autophagosome degradation through interaction 
with Beclin-UVRAG-Rubicon complex.11 
A rare form of HSP that develops in infancy or teenagers is caused by an autosomal-recessive 
single base deletion in the tectonin beta-propeller repeat-containing protein 2 gene (TECPR2 




patients suffered from mental disability, episodic central hypoventilation and gastroesophageal 
reflux disease. TECPR2 is a WD repeat protein that positively regulates autophagosome 
formation.  It binds to the COPII coat protein SEC24-related gene family, member D (SEC24D 
*607186) to maintain export from ER exit site (ERES) and its function was shown to be 
dependent on its interaction with lipidated LC3C.13 
Adaptor protein-4 (AP-4) deficiency syndrome is a subtype of complex HSP caused by 
autosomal recessive mutations of any subunit of AP-4 (SPG47 and 52 *614066, *614067).14 
Patients exhibit a complex phenotype, including early hypotonia progressing to hypertonia, 
intellectual disability, and microcephaly. As a coat protein, AP-4 is recruited onto membranes 
with their selected cargo to sort them into trafficking vesicles.  AP4 sorts mATG9 from the 
trans-Golgi network to maintain the axonal delivery of mATG9.15  
A clinically distinct autosomal recessive form of HSP, presenting as mutilating sensory 
neuropathy with spastic paraplegia, with evidence of severe posterior column atrophy, can be 
caused by autosomal recessive mutations of CCT5, the epsilon subunit of the cytosolic 
chaperonin-containing t-complex-1 (*610150).16 The CCT complex prevented accumulation 
various autophagy substrates primarily by mediating autophagy rather than through its direct 
chaperone activity preventing aggregation of such proteins. CCT5 promotes autophagosome 
degradation by regulating lysosome function, as it was shown that CCT5 disruption reduced 
the trafficking of lysosomal enzymes and the v-ATPase to lysosomes, possibly via interactions 
with cytoskeleton proteins.17  
Huntington’s disease 
Huntington’s disease is an inherited neurodegenerative proteinopathy caused by N-terminal 
polyglutamine tract expansions in huntingtin, resulting in chorea, dementia and psychiatric 
symptoms. The 5' end of the huntingtin gene has a block of repeated cytosine-adenine-guanine 
(CAG) trinucleotides. Normally, the CAG segment repeats itself about 10 to 35 times, while 
people with or more than 36 CAG trinucleotide repeats almost always develop Huntington 
disease. The average age of onset is 40 and is inversely correlated with the size of the CAG 
repeat.18 Juvenile forms of HD (onset <20 y), comprises 7% of HD cases, and is caused by high 
numbers of CAG gene repeats (60 or more).18 The clinical signs in pediatric HD differs from 
that of classical HD – chorea is often absent, with developmental delay, cerebellar ataxia, 




Wild-type huntingtin protein positively regulates selective autophagy in stress conditions by 
binding and releasing ULK1 from mTOR, and facilitating the interaction of p62 adaptor with 
LC3.19 Mutant huntingtin, which is aggregate-prone and toxic, can be cleared by autophagy.19 
In addition, the soluble huntingtin mutant protein is also toxic and competes with protective 
deubiquitinating enzyme Ataxin 3 (*607047) for binding with Beclin-1, thereby inhibiting 
autophagy. In the brain samples from Huntington’s disease patients, Beclin-1 levels and LC3-
II levels decreased.19   
Vici syndrome 
Vici syndrome is a severe, multisystem disorder resulting from an autosomal recessive 
mutations in EPG5 (P-granules autophagy protein 5 *615068), resulting in corpus callosum 
agenesis, cardiomyopathy, cataracts, oculocutaneous albinism and combined 
immunodeficiency. The presence of the additional three features of microcephaly, 
developmental delay and failure to thrive increases the likelihood of an EPG5 mutation to 
89%.20 The median survival for the disorder is 24 months, with recurrent sepsis and 
cardiorespiratory failure being the most common causes of premature mortality.20 EPG5 
encodes ectopic P-granules autophagy protein 5, a RAS-associated protein (Rab7 *602298) 
effector which is important for autophagosome-lysosome fusion. Loss of EPG5 activity caused 
elevated assembly of STX17-SNAP25-VAMP8 complexes, leading to abnormal fusion of 
autophagosomes with various endocytic vesicles.20  
 
Leukoencephalopathy (LE) 
Leukoencephalopathies comprise of a broad group of heterogeneous disorders of multiple 
aetiologies, characterized by white matter abnormalities in the central nervous system. A form 
of LE results from a missense vacuolar protein sorting 11 (VPS11 * 608549) mutation causing 
severe hypotonia, microcephaly, developmental delay and seizures. The 
C846G VPS11 mutation caused aberrant ubiquitination and accelerated its turnover, which 
impaired autophagy in human cells. VPS11 is a core subunit of endosomal tethering complexes, 
which are recruited onto autophagosomes and interact with SNAREs to mediate membrane 
fusion. As a component of HOPS complex, loss of VPS11 function caused accumulation of 





Lafora disease is a rare condition belonging to a group of progressive myoclonic epilepsies, 
resulting from autosomal recessive mutation in either EPM2A (*607566) or EPM2B 
(*608072), encoding laforin and malin, respectively. Typically, the disease onset is in late 
childhood, when first symptoms of myoclonus and occipital seizures appear, which can present 
as transient blindness or prominent visual hallucinations. This is followed by rapid dementia 
and worsening of intractable tonic-clonic seizures, eventually leading to death within 10 years 
of symptom onset. Patients manifest an accumulation of abnormally branched glycogen in the 
brain, liver and sweat glands in form of Lafora Bodies. Laforin, a dual-specificity protein 
phosphatase, has been shown to be involved in dephosphorylation of glycogen, ensuring its 
appropriate branching and solubility. Malin, which forms a complex with laforin, is an E3 
ubiquitin ligase and might play a role in activation of glycogen synthase as well as ubiquitin-
dependent proteasomal degradation of proteins involved in glycogen biosynthesis. While 
evidence suggests that aberrant glycogen accumulation might be crucial for the development 
of the disease, defects of autophagosome have also been demonstrated in this condition.22 
Tuberous sclerosis complex 
Tuberous sclerosis is an autosomal-dominant neurocutaneous disorder seen in 1:6000 births, 
characterised by benign tumour growth in multiple locations, including the brain, kidneys, 
lungs and heart. Affected patients tend to present with neurological symptoms, such as seizures, 
developmental delay, or autism. The disease-causing mutations for tuberous sclerosis have 
been mapped to TSC1 (*605284) and TSC2 (*191092), also known as hamartin and tuberin. 
Together with stabilising protein TBC1 domain family member 7 (TBC1D7 *612655), TSC1 
and TSC2 form a heterotrimeric complex, which negatively regulates Rheb GTPase, and in 
turn, the mTORC1 pathway, which is usually tightly controlled by signals including energy 
levels, nutritional status or growth factors. TSC1 or TSC2 mutations cause mTORC1 
hyperactivation, which reduces autophagosome formation, among other effects. Knowledge of 
this pathway has spawned multiple clinical trials utilising pharmacological mTORC1 
inhibitors, such as rapamycin and everolimus, which appear to reduce the size of the tumours 
in the brain and kidneys. However, the tumours tend to regrow after withdrawal of treatment, 






Charcot-Marie-Tooth (CMT) disease, also called hereditary motor and sensory neuropathy 
(HSMN), has a prevalence of 1:2500 individuals. Classically, CMT patients present with 
difficulty walking, high stepping gait, pes cavus, leg weakness and wasting of distal muscles 
of the upper and lower limb. Nerve conduction studies show either a symmetrical 
demyelinating, axonal or mixed pathology. To date, more than 70 genes and risk loci have been 
identified for the disease.24  
A mutation in dynein cytoplasmic 1 heavy chain 1 (DYNC1H1 *600112) coding for a 
cytoplasmic dynein causes hereditary childhood-onset spinal muscular atrophy with 
predominant involvement of the lower limbs, hence phenotypically resembling CMT.24 
Disruption of dynein function decreases autophagic clearance of aggregate-prone protein and 
increases lipidated LC3 levels, possibly through impairment of microtubule-dependent 
autophagosome-lysosome fusion.2  
Dynamin 2 (*602378)  mutations can also cause CMT associated with neutropenia and early-
onset cataracts, as well as dominant centronuclear myopathy, presenting as distal muscle 
weakness, pes cavus, facial weakness and ptosis. Loss of Dynamin 2 function causes the 
accumulation of immature autophagosomes, probably due to defective lysosome 
acidification.24 
Lysosome storage diseases 
Lysosome storage diseases are caused by genetic deficiencies of lysosomal proteins, including 
enzymes required for degradation in lysosomes, leading to the inappropriate storage of material 
in various parts of the body, including the nervous system. While a detailed discussion of this 
group of diseases is beyond the scope of this review, these do impact on autophagic flux, as 
lysosome storage diseases are associated with defective autophagosome-lysosome fusion.25 
Conclusions 
This review highlights that the autophagic process can be disrupted at multiple stages of its 
itinerary in different childhood-onset neurological diseases (Fig 1). This will likely lead to the 
accumulation of aggregation-prone proteins and an increased vulnerability to different stresses. 
While it is possible that pathology in many of these diseases may also be due to autophagy-
independent processes, the identification and characterisation of the autophagy defect may 
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Table 1: List of genes and diseases associated with impaired autophagy, showing where the defect 
may be in the autophagy pathway.  
Affected stage of 
autophagy pathway 
Gene Disease 
Initiation and signalling 
ATG5 Ataxia 
EPM2A/EPM2B Lafora disease  
TSC1/TSC2 Tuberous sclerosis 
Precursor formation 




SPG49/TECPR2 A rare form of hereditary spastic paraplegia 
Adaptors 
P62 
Childhood onset neurodegeneration with 
Ataxia 





EPG5 Vici Syndrome 
Autolysosome formation VPS11 Leukoencephalopathy 
Lysosome function 
CCT5 
Mutilating sensory neuropathy, a rare form of 
hereditary spastic paraplegia 
SPG11/SPG15 Hereditary spastic paraplegia 
SNX14 Cerebellar ataxia syndrome (SCAR17) 
Lysosome storage 
diseases (LSDs) that are 
neurological and 
childhood onset 
NPC1 Niemann-Pick Type C (NP-C) disease 
GBA Gaucher’s disease 
GALC Krabbe disease 
IDUA Mucopolysaccharidosis 
β-hexosaminidase GM2 Gangliosidoses 
TFEB LSDs including Gaucher’s disease 






Charcot-Marie-Tooth and Centronuclear 
Myopathy 
DYNC1H1 






Figure 1: The autophagic pathway, with known childhood neurological disorders affecting 
the process highlighted in red.  
Upstream autophagy initiation signals converge at ULK1/2 signalling pathway, which 
activates VPS34 complex by phosphorylation of FIP200, a member of VPS34 complex. 
VPS34 complex stimulates formation of PI3P, recruiting WIPI proteins and ATG5-12-16 
complex, which direct lipidation of the isolation membrane aiding the formation of a cup-
shaped phagophore. ATG5-12-16 complex then orchestrates expansion and maturation of the 
phagophore into a LC3-II containing autophagosome via series of conjugation processes, 
while substrates for autophagy are engulfed by the extending autophagosomal membrane. In 
the last step, the autophagosomes fuse with lysosomes, facilitating cargo degradation and 
recycling. 
 
Figure 2: Autophagosomes (yellow) and autolysosomes (red) in primary neurons. 
The image shows primary neurons from a transgenic mouse model expressing mRFP-GFP-
LC3 (ref. 17). This model allows one to distinguish non-acidified autophagosomes (red and 
green = yellow) from acidified autolysosomes (red only), as the GFP fluorescence is more 
rapidly quenched by the low lysosomal pH. 
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